Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jun;3(1):1-12.
doi: 10.3355/ce.2008.008.

Ivabradine: the evidence of its therapeutic impact in angina

Guillaume Marquis-Gravel  1 , Jean-Claude Tardif
Affiliations

Ivabradine: the evidence of its therapeutic impact in angina

Guillaume Marquis-Gravel et al. Core Evid. 2008 Jun.

Abstract

Introduction: Stable angina pectoris (SAP) is a widely prevalent disease affecting 30 000 to 40 000 per million people in Europe and the US. SAP is associated with reductions in quality of life and ability to work, and increased use of healthcare resources. Ivabradine is a drug with a unique therapeutic target, the I(f) current of the sinus node, developed for the treatment of cardiovascular diseases including SAP. It has an exclusive heart rate reducing effect, without any negative effect on left ventricular function or coronary vasodilatation.

Aims: The aim of this paper is to review the evidence concerning the use of ivabradine in the treatment of SAP.

Evidence review: Ivabradine is an effective antianginal and antiischemic drug, not inferior to the beta blocker atenolol and the calcium channel antagonist (CCA) amlodipine. It decreases the frequency of angina attacks and increases the time to anginal symptoms during exercise. Because of its exclusive chronotropic effect, ivabradine is not associated with the typical adverse reactions associated with beta blockers or other antianginal drugs.

Clinical value: Clinical evidence shows that ivabradine is a very good antiischemic and antianginal agent, being as effective as beta blockade and CCA therapy in controlling myocardial ischemia and symptoms of stable angina. Ongoing studies will determine the potential of ivabradine to improve morbidity and mortality in coronary artery disease and heart failure.

Keywords: If current; evidence; ivabradine; outcomes; stable angina pectoris; treatment.

PubMed Disclaimer

References

    1. AHA (American Heart Association) Heart disease and stroke statistics 2008. Available at: http://www.americanheart.org/presenter.jhtml?identifier=3000090 (accessed February 2008).
    1. Akhras F, Jackson G. Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina. Lancet. 1991;338:1036–1039. - PubMed
    1. Borer JS, Fox K, Jaillon P, Lerebours G, Ivabradine Investigators Group Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107:817–823. - PubMed
    1. Brogden RN, Benfield P. Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease. Drugs. 1996;51:792–819. - PubMed
    1. Campeau L. Letter: grading of angina pectoris. Circulation. 1976;54:522–523. - PubMed

LinkOut - more resources